Translational Research
-
Is The Sensitivity Of Optical Biosensors Important?
2/17/2022
Explore why the sensitivity of optical biosensors is important for not just small molecules or fragment-based interactions but also for larger molecular entities.
-
How To Best Optimize mRNA Production Workflows
4/11/2023
Multiple steps in the mRNA manufacturing process can appear more complex than they have to be. Learn how to simplify your approach and produce the best possible mRNA vaccines and therapeutics.
-
Analytics & Assays: Defining mRNA Therapeutic Impurities Early & Often
12/5/2023
mRNA therapeutics present a whole new safety paradigm not seen in vaccine applications. In this segment, Combined Therapeutics CSO Thomas Van Cott, Ph.D. and Omega Therapeutics Executive Director, Process Development and Analytical Sciences Jeff Atkinson, Ph.D. address the nuances of mRNA therapeutic analytics and assays.
-
Why iPSC Is Research Thriving
5/23/2025
In this first segment of Cell & Gene Live, Unlocking the Potential of iPSC Therapies in Regenerative Medicine, Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas highlight the transformative potential of regenerative medicine and iPSC-based therapies. They emphasize the versatility and scalability of pluripotent stem cells, particularly for allogeneic applications that could eliminate the need for immunosuppression. These advances hold promise for treating complex diseases like diabetes, multiple sclerosis, and cardiac conditions, with the goal of making therapies more accessible and impactful on a global scale.
-
An All-In-One Solution For Residual DNA Quantitation
5/22/2025
Explore an all-in-one solution for residual DNA quantitation with a 3D lab tour with virtual demos, videos, and interactive instrument guides to experience the full workflow.
-
Audience Q&A | Inside The Most Promising Non-Viral Approaches To Genetic Engineering
11/9/2024
Expert panelists, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics, provided detailed responses to our audience questions on electroporation, CRISPR, delivery technologies beyond LNPs, CAR T-cell therapy, and more.
-
Why Material Definitions Matter In Cell And Gene Therapy
4/1/2026
In this first segment of Cell & Gene Live, Anthony Blaszczyk, Ph.D., Senior Scientist at the U.S. Pharmacopeia, and Basak Clements, Ph.D., Founder and Senior Advisor at biomatria, were joined by Cell & Gene Chief Editor Erin Harris to discuss why cell and gene therapy, clearly defining raw, starting, and ancillary materials, and using those terms consistently, is critical.
-
GLP And The Impact To Start Up Companies
4/18/2022
Good Laboratory Practice is often used in laboratories and is necessary for specific investigations. What does it mean? And how can it help start-up companies? Watch this video to learn more.
-
Safety And Efficacy Advancements In Genome Editing
11/9/2024
Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics shares his take on the high frequency of productive edits for base editing. In addition, Celularity’s Chairman, Founder, and CEO, Dr. Robert Hariri, shares how he sees non-viral gene delivery methods potentially enhancing cell therapy platforms.
-
Real-Time Monitoring And Automated Sampling For Enhanced Efficiency
3/17/2025
Integrating real-time, in-line monitoring with automated sampling in bioprocessing enhances efficiency and precision. Discover how advanced spectroscopy provides non-destructive insights to optimize cell growth and productivity.